Grazoprevir Anhydrous
drug drugOn this page
Also known as MK-5172MK-5172 ANHYDROUSGrazoprevirGrazoprevir hydrateÊGrazoprevir hydrateÂNAGrazoprevir Hydrate
Summary
Grazoprevir Anhydrous (CHEMBL2063090) is an approved small-molecule antiviral drug; indicated across 2 conditions including chronic hepatitis c virus infection and hepatitis c virus infection.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Indications: 2 conditions
- Clinical trials: 46
- Chemistry: 766.9 Da · C38H50N6O9S
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2063090 |
| Name | Grazoprevir Anhydrous |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | no |
| PubChem CID | 44603531 |
| ChEBI | CHEBI:132975 |
| Molecular formula | C38H50N6O9S |
| Molecular weight | 766.9 |
| InChIKey | OBMNJSNZOWALQB-NCQNOWPTSA-N |
SMILES: CC(C)(C)[C@H]1C(=O)N2C[C@@H](C[C@H]2C(=O)N[C@@]3(C[C@H]3C=C)C(=O)NS(=O)(=O)C4CC4)OC5=NC6=C(C=CC(=C6)OC)N=C5CCCCC[C@@H]7C[C@H]7OC(=O)N1
IUPAC name: (1R,18R,20R,24S,27S)-24-tert-butyl-N-[(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-ethenylcyclopropyl]-7-methoxy-22,25-dioxo-2,21-dioxa-4,11,23,26-tetrazapentacyclo[24.2.1.03,12.05,10.018,20]nonacosa-3,5(10),6,8,11-pentaene-27-carboxamide
ChEBI definition: An azamacrocyclic compound that is a hepatitis C protease inhibitor used in combination with elbasvir (under the brand name Zepatier) for treatment of chronic HCV genotypes 1 or 4 infection in adults.
Pharmacological roles (ChEBI): antiviral drug, hepatoprotective agent, hepatitis C protease inhibitor.
Also known as: Grazoprevir anhydrous, MK-5172, MK-5172 ANHYDROUS, GRAZOPREVIR ANHYDROUS, Grazoprevir, GRAZOPREVIR, Grazoprevir hydrateÊ, Grazoprevir hydrateÂ, NA, Grazoprevir Hydrate
Parent form; salt/anhydrous children: CHEMBL2063078, CHEMBL3039533
Patent coverage: 445 distinct patent families (1,089 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).
| Indication | Phase | MONDO | EFO |
|---|---|---|---|
| chronic hepatitis C virus infection | 4 | MONDO:0005354 | EFO:0004220 |
1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| hepatitis C virus infection | 3 | MONDO:0005231 | EFO:0003047 |
Clinical trials
Total trials: 46.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 15 |
| PHASE3 | 9 |
| PHASE4 | 7 |
| Not specified | 7 |
| PHASE1 | 5 |
| PHASE2/PHASE3 | 3 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02940691 | PHASE4 | TERMINATED | Scale-up of Treatment of Hepatitis C Infection Among People Who Inject Drugs |
| NCT03022006 | PHASE4 | UNKNOWN | Safety and Effect of Elbasvir/Grazoprevir Combination Therapy in Hemodialysis Patients With Chronic Hepatitis C |
| NCT03098121 | PHASE4 | COMPLETED | Efficacy and Tolerability of Grazoprevir and Elbasvir in Patients With Chronic Genotype 1 HCV and HIV Co-infection |
| NCT03105349 | PHASE4 | WITHDRAWN | A Clinical Trial of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotypes 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A |
| NCT03359746 | PHASE4 | UNKNOWN | Grazoprevir/Elbasvir for Treatment of Hepatitis C Virus Genotype 4 Post Kidney Transplant |
| NCT03585101 | PHASE4 | WITHDRAWN | A Single-arm Evaluation of the Effect of HCV Treatment on Cardiovascular Disease Risk |
| NCT03723824 | PHASE4 | TERMINATED | Grazoprevir/Elbasvir for Genotype 1b Chronic Hepatitis C After Liver or Kidney Transplantation |
| NCT02092350 | PHASE2/PHASE3 | COMPLETED | Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052) |
| NCT02105701 | PHASE3 | COMPLETED | Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068) |
| NCT02115321 | PHASE2/PHASE3 | COMPLETED | Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Chronic Hepatitis C Participants With Child-Pugh (CP)-B Hepatic Insufficiency (MK-5172-059) |
| NCT02203149 | PHASE2/PHASE3 | COMPLETED | Study of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Japanese Participants With Chronic Hepatitis C (MK-5172-058) |
| NCT02204475 | PHASE3 | WITHDRAWN | Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066) |
| NCT02251990 | PHASE3 | COMPLETED | Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination in Treatment-Naïve Hepatitis C Virus Participants (MK-5172-067) |
| NCT02252016 | PHASE3 | COMPLETED | Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065) |
| NCT02358044 | PHASE3 | COMPLETED | Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077) |
| NCT02600325 | PHASE3 | COMPLETED | Dutch Acute HCV in HIV Study (DAHHS-2): Grazoprevir/Elbasvir for Acute HCV |
| NCT02785666 | PHASE3 | COMPLETED | Swiss HCVree Trial |
| NCT02890719 | PHASE3 | WITHDRAWN | Pilot Study Evaluate Efficacy of Grazoprevir + Elbasvir for 12 or 16 Weeks in Liver Transplant Recipients. |
| NCT02897596 | PHASE3 | UNKNOWN | Efficacy of GZR/EBR in Early Chronic Hepatitis C in HIV/HCV Co-infected Patients |
| NCT01353911 | PHASE2 | COMPLETED | Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003) |
| NCT01440595 | PHASE2 | TERMINATED | Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012) |
| NCT01710501 | PHASE2 | COMPLETED | A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038) |
| NCT01716156 | PHASE2 | COMPLETED | A Study of Different Durations of Treatment With Grazoprevir (MK-5172) in Combination With Ribavirin in Participants With Chronic Hepatitis C (MK-5172-039) |
| NCT01717326 | PHASE2 | COMPLETED | A Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) ± Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035) |
| NCT01932762 | PHASE2 | COMPLETED | Efficacy and Safety of Combination Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047) |
| NCT02105454 | PHASE2 | COMPLETED | Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin in Participants With Chronic Hepatitis C Who Failed Prior Direct-Acting Antiviral Therapy (MK-5172-048) |
| NCT02133131 | PHASE2 | COMPLETED | Efficacy and Safety of Grazoprevir (MK-5172), Elbasvir (MK-8742), and Sofosbuvir for Chronic Infection With Hepatitis C Virus Genotypes 1 and 3 (MK-5172-074) |
| NCT02332707 | PHASE2 | COMPLETED | Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011) |
| NCT02332720 | PHASE2 | COMPLETED | Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012) |
| NCT02601573 | PHASE2 | COMPLETED | Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic Hepatitis C Virus (HCV) Genotype 3 (GT3) Infection (MK-5172-083) |
| NCT02647632 | PHASE2 | COMPLETED | Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir |
| NCT02886624 | PHASE2 | COMPLETED | Short Duration Therapy of Acute Hepatitis C Genotypes 1 or 4 |
| NCT02940496 | PHASE2 | COMPLETED | Pembrolizumab (MK-3475) in Hepatocellular Carcinoma |
| NCT03379506 | PHASE2 | COMPLETED | Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079) |
| NCT00998985 | PHASE1 | COMPLETED | A Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Male Participants (MK-5172-004) |
| NCT01390428 | PHASE1 | COMPLETED | Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Grazoprevir (MK-5172-013) |
| NCT01537900 | PHASE1 | COMPLETED | A Multiple Dose Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Participants (MK-5172-010) |
| NCT01547312 | PHASE1 | WITHDRAWN | Evaluation of Hepatic Pharmacokinetics for Grazoprevir (MK-5172) in Participants With Chronic Hepatitis C (MK-5172-022) |
| NCT01937975 | PHASE1 | COMPLETED | The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050) |
| NCT01667081 | Not specified | COMPLETED | Durability of Virologic Response and/or Viral Resistance Patterns in Participants With Chronic Hepatitis C Who Have Been Previously Treated With Grazoprevir (MK-5172) (MK-5172-017) |
| NCT02333292 | Not specified | COMPLETED | Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions |
| NCT03110055 | Not specified | UNKNOWN | the Effect of Grazoprevir/Elbasvir and TACE vs. TACE Alone in Prolonging Survival of Patients With Non-resectable HCV Associated HCC. |
| NCT03111966 | Not specified | COMPLETED | Effectiveness, Safety and Clinical Outcomes of Elbasvir/Grazoprevir: Results From a Spanish Real World Cohort |
| NCT03145623 | Not specified | COMPLETED | Retrospective Efficacy and Safety Study With Elbasvir/Grazoprevir in HCV-infected Patients With Chronic Kidney Disease |
| NCT03433326 | Not specified | UNKNOWN | Grazoprevir and Elbasvir Without Ribavirin for 12 Weeks in Patients With HCV-related Cryoglobulinemic Nephropathy |
| NCT03706222 | Not specified | COMPLETED | Drug-Drug Interactions of Grazoprevir/Elbasvir in Taiwan |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline, but PharmGKB curates 0 clinical and 3 variant annotation(s) for this drug (gene-keyed; see PharmGKB).
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Indicated for: chronic hepatitis C virus infection
- In clinical trials for: hepatitis C virus infection